The global diffuse large B-cell lymphoma therapeutics market is experiencing rapid growth, fueled by a elevated prevalence of the disease and advancements in treatment options. The market is characterized by a diverse landscape of players, including leading pharmaceutical companies and emerging biotech firms. Key factors shaping the market include